Literature DB >> 31976142

A Novel Pathogenic Variant of the CFTR Gene in a Patient with Cystic Fibrosis Phenotype-c.4096A > T.

Ahmet Burak Arslan1, Ayşe Gül Zamani1, Sevgi Pekcan2, Mahmut Selman Yıldırım1.   

Abstract

Cystic fibrosis is a chronic multisystemic disease originating from functional alterations in CFTR (cystic fibrosis transmembrane conductance regulator) protein. To date, more than 300 pathogenic variants have been described in the literature. However, the diagnosis of CF, which was thought to become easier after the CFTR gene was identified, became more complicated due to the enormous amount of variations. In this study, we present a patient whose clinical findings were consistent with cystic fibrosis (CF) and showed a homozygous missense change that is not previously reported in the CFTR gene as pathogenic. In the next-generation sequencing analysis, homozygous c.4096A > T single-nucleotide exchange (I1366F [p.Ile1366Phe], missense) was shown in both alleles of the patient' CFTR gene. According to our database analysis, this variant has not yet been previously reported (VarSome, ClinVar, MutationTaster, Ensembl, dbSNP, PubMed). We do consider the change as pathogenic since the patient's findings were compatible with CF and the data analysis was in favor of pathogenicity. The most recent consensus report published in 2017 emphasized the importance of CFTR gene analysis, and this study emphasizes the difficulties of associating CFTR gene variations with a clinical picture and constitutes a new data on the genotype-phenotype correlation of CFTR variants. Also, considering the frequency of CF (according to World Health Organization data, every 1 out of 2,000-3,000 infants is born with CF in European Union countries and every 1 out of 3,500 in the United States) as well as the increasing rate of molecular studies performed on CF patients worldwide, reporting novel variation has an additional value. © Thieme Medical Publishers.

Entities:  

Keywords:  CFTR (cystic fibrosis transmembrane conductance regulator) ; cystic fibrosis; next-generation sequencing; novel; pathogenic variant

Year:  2019        PMID: 31976142      PMCID: PMC6976330          DOI: 10.1055/s-0039-1694964

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  22 in total

Review 1.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

Authors:  B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-04       Impact factor: 4.406

2.  Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles.

Authors:  Vito Terlizzi; Giuseppe Castaldo; Donatello Salvatore; Marco Lucarelli; Valeria Raia; Adriano Angioni; Vincenzo Carnovale; Natalia Cirilli; Rosaria Casciaro; Carla Colombo; Antonella Miriam Di Lullo; Ausilia Elce; Paola Iacotucci; Marika Comegna; Manuela Scorza; Vincenzina Lucidi; Anna Perfetti; Roberta Cimino; Serena Quattrucci; Manuela Seia; Valentina Maria Sofia; Federica Zarrilli; Felice Amato
Journal:  J Med Genet       Date:  2016-10-13       Impact factor: 6.318

3.  Clinical investigational studies for validation of a next-generation sequencing in vitro diagnostic device for cystic fibrosis testing.

Authors:  Daniel S Grosu; Lynda Hague; Manjula Chelliserry; Kristina M Kruglyak; Ross Lenta; Brandy Klotzle; Jonathan San; Wendy M Goldstein; Sharmili Moturi; Patricia Devers; Julie Woolworth; Eric Peters; Barbara Elashoff; Jay Stoerker; Daynna J Wolff; Kenneth J Friedman; W Edward Highsmith; Erick Lin; Frank S Ong
Journal:  Expert Rev Mol Diagn       Date:  2014-06       Impact factor: 5.225

Review 4.  New clinical diagnostic procedures for cystic fibrosis in Europe.

Authors:  K De Boeck; N Derichs; I Fajac; H R de Jonge; I Bronsveld; I Sermet; F Vermeulen; D N Sheppard; H Cuppens; M Hug; P Melotti; P G Middleton; M Wilschanski
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

5.  Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis.

Authors:  Juan F Gallegos-Orozco; Catherine E Yurk; Nulang Wang; Jorge Rakela; Michael R Charlton; Garry R Cutting; Vijayan Balan
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

6.  Cystic fibrosis genetic counseling difficulties due to the identification of novel mutations in the CFTR gene.

Authors:  Myrto Poulou; Irini Fylaktou; Maria Fotoulaki; Emmanuel Kanavakis; Maria Tzetis
Journal:  J Cyst Fibros       Date:  2012-02-11       Impact factor: 5.482

7.  Next generation diagnostics of cystic fibrosis and CFTR-related disorders by targeted multiplex high-coverage resequencing of CFTR.

Authors:  D Trujillano; M D Ramos; J González; C Tornador; F Sotillo; G Escaramis; S Ossowski; L Armengol; T Casals; X Estivill
Journal:  J Med Genet       Date:  2013-05-17       Impact factor: 6.318

8.  Bacteremia in patients with cystic fibrosis.

Authors:  M M McCarthy; M H Rourk; A Spock
Journal:  Clin Pediatr (Phila)       Date:  1980-11       Impact factor: 1.168

9.  Next generation sequencing to determine the cystic fibrosis mutation spectrum in Palestinian population.

Authors:  O Essawi; M Farraj; K De Leeneer; W Steyaert; K De Pauw; A De Paepe; K Claes; T Essawi; P J Coucke
Journal:  Dis Markers       Date:  2015-01-26       Impact factor: 3.434

Review 10.  Next-generation sequencing technologies: breaking the sound barrier of human genetics.

Authors:  El Mustapha Bahassi; Peter J Stambrook
Journal:  Mutagenesis       Date:  2014-09       Impact factor: 3.000

View more
  1 in total

1.  A Cross-Sectional Study of the Marital Attitudes of Pregnant Women at Risk for Cystic Fibrosis and Psychological Impact of Prenatal Screening.

Authors:  Zoran Laurentiu Popa; Madalin-Marius Margan; Izabella Petre; Elena Bernad; Lavinia Stelea; Veronica Daniela Chiriac; Marius Craina; Ioana Mihaela Ciuca; Anca Mihaela Bina
Journal:  Int J Environ Res Public Health       Date:  2022-07-17       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.